STAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilot
Stat News • 3/2/2026 – 3/3/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
3
2026-03-022026-03-03
Lindy Score Breakdown (V4.2)
4h
Age
1
Sources
from cluster
2
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier97% (0.5^2/48)
Hero EligibleYes
Story Timeline
- 2026-03-02
- 2026-03-03STAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilot (current)
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 4 sources
STAT+: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more
Stat News • Today
STAT+: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says
Stat News • Today
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA
Stat News • 1 day ago
Breaking Similar stories
STAT+: Federal Medicaid audit finds massive overpayment for autism therapy in Colorado
Stat News • 1 day ago
STAT+: FDA grants ‘breakthrough’ status to generative AI chatbot for surgical patients
Stat News • Today
STAT+: MAHA goes global: Inside the rise of the Make Europe Healthy Again movement
Stat News • Today
STAT+: CMS halts enrollment in Elevance’s Medicare Advantage plans, citing years of misconduct
Stat News • 1 day ago
Opinion: STAT+: 6 key dilemmas as human embryo models get ever closer to the real thing
Stat News • Today
STAT+: FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says
Stat News • Today
STAT+: HHS starts phasing out Anthropic’s Claude
Stat News • Today
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more
Stat News • Today
STAT+: Prime Medicine to seek approval for gene editing treatment after two-patient trial
Stat News • Today